JVM Global Inc

JVM Global Inc is managed by a group of dedicated professionals having rich experience of over years in IT and Non- IT consulting. JVM Global is a company that people can anchor to in moments of triumph, struggle, and every time in between. Whoever you are and wherever you come from, you matter to us and we have your back. We specialize in Engineering, Validation, Regulatory, IT and NON-IT related areas primarily focused on Pharmaceutical / Life Sciences and Medical device companies. We are E-verified company. Our business is matching smart people with great jobs, from the executive office to the manufacturing floor. We use innovative technologies and a passion for people to provide you with the best experience possible.

DMD America, Inc. - AnalySource.com

DMD America began a partnership with First Databank, Inc. in the mid-1990’s en route to becoming the industry’s first web-based source of drug pricing data with the launch of AnalySource® Daily in 2000. Our goal at DMD America has always been to provide powerful yet user-friendly drug pricing tools to deliver not only data, but information and competitive intelligence to our users. In doing so, we have grown into an industry leader and now offer online drug pricing tools which includes a suite of different AnalySource® solutions, customized data pulls and reports, and government compliance forms. Also see our NEW, public-facing, Rx Drug Pricing Dashboard at https://AnalySource-Public.com

Radionetics Oncology

Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.

Olon USA

Who we are: On June 9, 2017, Olon S.p.A., a leading Active Pharmaceutical Ingredients (API) contract development and manufacturing organization (CDMO) and Generics supplier, announced the acquisition of Ricerca Biosciences’ Chemical Division of the contract research (CRO) and CDMO based in Concord, Ohio, USA. This acquisition strengthens the service offering of Olon for the pharmaceutical and biotech industry and benefits Ricerca Biosciences' customer base by providing large-scale manufacturing capabilities in Europe. Olon USA is a US-based CDMO supporting the development and manufacture of APIs and performance materials in support clinical supply, market development and commercial distribution. Olon USA’s extensive process/synthetic chemistry, analytical chemistry and engineering expertise provides a synergy that excels at first-time scale-ups and subsequent development of safe, reliable, robust and cost-effective manufacturing processes. For more than 25 years, Olon USA has a record of on-time delivery and quality, providing comprehensive support and problem solving for successful development, scale-up and process-optimized manufacture of pharmaceutical ingredients. Company Details Website: http://www.olon-usa.com Location: Concord, OH Florham Park, NJ

Wockhardt Ltd.

Wockhardt is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Specialty Hospitals. Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 3000 Wockhardt Associates from 21 different nationalities globally. It has 3 research centers and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. Headquartered in Mumbai, India, Wockhardt has full-fledged operations in the USA, UK, Ireland and France. It also has its marketing presence in emerging markets of Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. Wockhardt’s core business is innovation. It uses science and technology to develop medicines and other products that improve the quality of millions people’s lives through better health. Wockhardt aspires to create a healthier world. Its strategic vision of ‘More & More with Less & Less’ has transformed into new ways of thinking, a new journey for growth, medical breakthroughs for patients and continuing value for all stakeholders.